EHA 2018 | MPN therapies: the current landscape
Claire Harrison
• 14 Jun 2018
Treatment of myeloproliferative neoplasms (MPNs) is expanding to include several exciting new therapies. We spoke to Claire Harrison, MD, FRCP, FRCPath, from Guy’s and St Thomas’ Hospital, London, UK at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, about the most interesting therapies in the field at the moment. She discusses: JAK inhibitors like fedratinib and pacritinib; interferon both as a monotherapy and in combination with ruxolitinib; combination therapies with ruxolitinib and venetoclax, azacitidine or PI3K inhibitors; and MDM2 inhibitors like idasanutlin.
